Today, Neogen Corporation, an innovative leader in food safety solutions, announced it has entered into a definitive agreement to sell its global genomics business to Zoetis Inc., the world’s leading animal health company, for $160 million, subject to customary closing adjustments.
Neogen’s planned divestiture, which had been previously announced, was part of the company’s portfolio review strategy to simplify the business and focus on core strategic markets.
“Neogen’s genomics business (GeneSeek) has been a pioneer in advanced DNA testing for livestock and has set a high standard for innovation across the livestock sector, with globally recognized solutions spanning genomic prediction, herd improvement and data integration,” says Tom Schultz, Neogen head of commercial global genomics."We’re excited to build on that foundation in our future with Zoetis and to continue advancing tools that strengthen animal health, performance and overall profitability. Customers can expect a thoughtful transition and continued excellent service,”
According to a Zoetis release, “This acquisition aligns directly with Zoetis’ strategy to drive future livestock innovation through genomics, reinforcing its commitment to livestock producers worldwide and advancing its precision animal health portfolio. By integrating Neogen’s genomic technologies and data solutions, Zoetis is expanding its capabilities to deliver predictive insights, individualized care and greater value to customers across major livestock and companion animal species.”
Neogen’s genomics business serves customers in more than 120 countries through its five laboratories in the U.S., Brazil, Australia, China and the United Kingdom, as well as an office location in Canada. The business leverages a comprehensive genotyping platform of fixed array and sequencing technologies, as well as software solutions that empower customers to make informed and data-driven decisions. The business is a leader in U.S. beef and dairy genomics, and its cutting-edge technologies enable highly accurate, scalable genetic testing and deeper insights into animal health, productivity and sustainability.
“This transaction is part of the company’s strategic portfolio review and allows the company to accelerate de-leveraging and improve profitability going forward,” says Mike Nassif, Neogen’s chief executive officer and president. “Furthermore, this deal allows us to focus in areas where the company has the most significant competitive advantage and further leverage our core capabilities in food and animal safety. We are committed to a smooth transition for customers, employees and other stakeholders, and believe the business is well positioned to thrive under Zoetis’ ownership.”
GeneSeek has been a pioneer in advanced DNA testing for livestock and companion animal industries, leveraging a global presence to deliver highly accurate, data-driven insights that contribute to improved animal performance and health, as well as profitability, in the beef, dairy and other industries. Through the flagship Igenity and GGP portfolio and rapid turnaround times, the business offers returns-focused genomic tools and globally recognized standards in genomic prediction to accelerate herd improvement and enable genomics trait screening. Supported by the Encompass platform for genomic data integration and strategic partnerships advancing DNA-backed traceability, GeneSeek is committed to continued innovation and scientific excellence.
“We’re excited to build on our innovative genomics portfolio offerings in our future with Zoetis and to continue advancing tools that strengthen overall animal health, performance, and profitability,” Schultz says. “At Zoetis, genomics becomes a core part of a company fully dedicated to animal health. Zoetis brings deep scientific capabilities, operational scale, and a long-term commitment to genetics and data.”
Jamie Brannan, Zoetis chief commercial officer, adds, “The addition of Neogen’s genomics business strengthens our commitment to advancing animal health through innovation, data and technology. As we continue to grow our leading innovative solutions in Precision Animal Health, this acquisition brings complementary capabilities that expand predictive insights and individualized care, enabling us to deliver added value to customers. Together, we are shaping the future of animal health, empowering customers with the tools they need to support healthier animals and sustainable livestock production globally.”
The transaction is expected to close by the end of the first half of the company’s 2027 fiscal year, subject to regulatory approval and customary closing conditions. The net proceeds from the transaction are expected to be used primarily for debt reduction. The Neogen genomics business generated approximately $90 million in sales during fiscal year 2025.
“At the time of the announcement, nothing will change,” Schultz explains. “Our customers’ contacts and ordering processes remain the same — products, services and support also remain the same. Customers can expect a thoughtful transition, continued service continuity, and future benefits from Zoetis’ focus in the business. Any changes will be communicated well in advance.”
Zoetis says it is committed to a seamless integration, supporting continuity for colleagues and customers, and building on Neogen’s legacy of innovation in genomics.
